Full Press Release Details
TapImmune Announces Change in Management
and Board of Directors
April 28, 2017, Jacksonville, FL,,
TapImmune Inc. (NASDAQ: TPIV), a clinical-stage
immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for
the treatment of cancer and metastatic disease, has announced that on April 27, 2017, Dr. John Bonfiglio resigned as Chief Operating
Officer, President and director of TapImmune Inc. to pursue other opportunities.
Speaking for the Board of Directors, Chairman and CEO of TapImmune
Dr. Glynn Wilson stated, "We have been fortunate to have John serve the Company initially as a consultant and subsequently
as an officer and director. During John's tenure as part of our management team, the Company successfully optimized and scaled
up GMP manufacturing operations, allowing us to enter multiple Phase 2 clinical studies and to be listed on Nasdaq Capital Markets.
As the company transitions into a focus on later stages of clinical development, I want to thank John and wish him the best in
his future endeavors."
Dr. Bonfiglio stated "I am pleased to have had the opportunity
to support TapImmune and its clinical programs. I remain optimistic about the Company's future and the prospects for its
next-generation vaccine technologies."
In connection with Dr. Bonfiglio's resignation, the size
of the Board was reduced from seven members to six members. Dr. Wilson, was appointed to serve as the Company's President
due to the vacancy created by Dr. Bonfiglio's resignation.
About TapImmune Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies
for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products
comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T
cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression
systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.
Please visit the Company's website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information
within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's
expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations
as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking
statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially
from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth
in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The
Company assumes no obligation to update the forward-looking statements.